Kelly Chibale

Kelly Chibale is a full Professor of Organic Chemistry at the University of Cape Town (UCT), holding the Neville Isdell Chair in African-centric Drug Discovery & Development. He serves as Director of the UCT Holistic Drug Discovery and Development (H3D) Centre, founding Director of the South African Medical Research Council Drug Discovery & Development Research Unit, and Founder/CEO of the H3D Foundation. He is a Full Member of the UCT Institute of Infectious Disease & Molecular Medicine and a Schmidt Sciences AI2050 Senior Fellow.

Chibale obtained his PhD in Synthetic Organic Chemistry from the University of Cambridge, followed by postdoctoral research at the University of Liverpool and The Scripps Research Institute. He held visiting positions at UC San Francisco, University of Pennsylvania, and Pfizer.

His research focuses on drug discovery and developing models to improve therapeutic outcomes for African populations, emphasizing infectious diseases and health equity.

Awards & Honors

• Royal Society Africa Prize (2023)
• Schmidt Sciences AI2050 Senior Fellowship (2023)
• Elected to US National Academy of Medicine (2024) and US National Academy of Sciences (2025)
• Honorary Doctorates: University of Basel (2023), Leiden University (2025)
• South African Medical Research Council Gold Medal (2016)
• Fortune World's 50 Greatest Leaders (2018)

He leads scientific advisory boards for INTREPID Alliance, Helmholtz Institute (Germany), and Global Health Drug Discovery Institute (China). As Editor-in-Chief of ACS Medicinal Chemistry Letters, he is the first African to lead an American Chemical Society journal.